Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)

v3.24.0.1
Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share            
Net earnings, including noncontrolling interest $ 27,465 $ 50,993 $ 50,005 $ 89,734 $ 78,459 $ 139,739
Less net earnings (loss) attributable to noncontrolling interest           179
Net earnings attributable to Bio-Techne 27,465   50,005   78,459 139,560
Income allocated to participating securities (3)   (10)   (13) (35)
Income available to common shareholders $ 27,462   $ 49,995   $ 78,446 $ 139,525
Weighted-average shares outstanding - basic (in shares) 157,533   157,011   157,826 156,887
Earnings per share - basic (in shares) $ 0.17   $ 0.32   $ 0.50 $ 0.89
Income available to common shareholders $ 27,462   $ 49,995   $ 78,446 $ 139,525
Dilutive effect of stock options and restricted stock units (in shares) 2,527   4,739   3,175 4,879
Weighted-average common shares outstanding - diluted (in shares) 160,060   161,750   161,001 161,766
Earnings per share - diluted (in shares) $ 0.17   $ 0.31   $ 0.49 $ 0.86